SAR447537 (INBRX-101)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for SAR447537 (INBRX-101), covering 2025-08-11 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema [Phase 2]